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Abstract
Background: Delivering Reproductive Health Results(DRHR) programme used social franchising (SF) and social
marketing (SM) approaches to increase the supply of high quality family planning services in underserved areas of
Pakistan. We assessed the costs, cost-efficiency and cost-effectiveness of DRHR to understand the value for money
of these approaches.
Methods: Financial and economic programme costs were calculated. Costs to individual users were captured
in a pre-post survey. The cost per couple years of protection (CYP) and cost per new user were estimated as
indicators of cost efficiency. For the cost-effectiveness analysis we estimated the cost per clinical outcome averted and
the cost per disability-adjusted life year (DALY) averted.
Results: Approximately £20 million were spent through the DRHR programme between July 2012 and September
2015 on commodities and services representing nearly four million CYPs. Based on programme data, the cumulative
cost-efficiency of the entire DRHR programme was £4.8 per CYP. DRHR activities would avert one DALY at the cost of
£20. Financial access indicators generally improved in programme areas, but the magnitude of progress varies across
indicators.
Conclusions: The SF and SM approaches adopted in DRHR appear to be cost effective relative to comparable
reproductive health programmes. This paper adds to the limited evidence on the cost-effectiveness of different models
of reproductive health care provision in low- and middle-income settings. Further studies are needed to nuance the
understanding of the determinants of impact and value for money of SF and SM.
Keywords: Reproductive health, Social franchising (SF), Social marketing (SM), Value for money, Pakistan,
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Background
Despite evidence of progress in improving maternal health
outcomes since 1990, close to 300,000 maternal deaths
occur every year [1, 2]. Globally, an estimated 77% of
women of reproductive age have their family planning
(FP) needs met with a modern method [3], however
geographic, demographic and socioeconomic disparities
are significant [4].
While there is agreement that contraceptives are
cost-efficient and cost-effective, a research gap persists as
to the costs and impacts of demand creation strategies for
contraceptives to increase service coverage [5–7]. In rec-
ognition that the mere availability of health services and
products is necessary, but insufficient to improve health
status, demand creation strategies aim to improve aware-
ness and acceptability among target beneficiaries – they
include, but are not limited to “development of advocacy
materials for family planning; dissemination of appropriate
messages for family planning by community health workers;
advocacy on family planning at the community levels to
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involve the formal and informal leaders; sensitization and
awareness creation through community radio, radio drama,
television drama, etc.; targeting of special groups including
male motivation etc., in the promotion of contraceptives;
training of community health/extension workers and others
for promotion of family planning; and social marketing of
modern contraceptives” [8]. Social marketing (SM) and so-
cial franchising (SF) are two such demand creation strat-
egies. SM uses approaches from commercial marketing to
provide contraceptive products and services at subsidized
rates; a SM organization would often be responsible for
managing the implementation of marketing approaches
such as branding and community mobilization through a
standardized protocol. Under SF, outlets (e.g. NGOs, clinics,
pharmacies) run by service providers (e.g. nurses, commu-
nity health workers) deliver family planning services under
contracts with an agency or franchisor providing standard-
ized products and services under a common brand [9].
Despite several decades of implementation experience [10,
11], there is yet little published evidence on whether SM
and SF are effective and cost-effective approaches to deliver
FP commodities and services. For instance, a recent system-
atic review of five private sector models of delivering basic
care, including SM and SF, confirmed that the impact and
economic evidence base remains weak [12]. Another sys-
tematic review focused on SF found an equally weak evi-
dence base [13], with at least two other quasi-experimental
evaluation published since showing no overall impact of SF
on FP coverage [14, 15].
Maternal, child and infant mortality outcomes are poor
in Pakistan and progress towards Millennium Develop-
ment Goals 4 and 5 has been slow [16, 17]. Demographic
and Health Survey 2012–2013 results pointed to a 35%
contraceptive prevalence rate (CPR) and a 26% rate of
modern contraceptive method use [18]. Low CPRs in
parts of Pakistan may be attributed to insufficient physical
access to methods, health concerns, cultural or religious
restrictions, or the male partner opposing contraceptives
use [19]. This points to a deeper issue of low demand for
contraceptives, suggesting the need for behaviour change
communication interventions alongside efforts to improve
the supply of reproductive health (RH) services.
Under the Lady Health Workers (LHWs) Programme,
launched in 1994 and later renamed the National Family
Planning and Primary Health Care Program, LHWs cre-
ate awareness through door-to-door meetings and pro-
vide short-term, modern FP supplies to women who
express an intention to adopt FP. Although the
programme was found to be associated with increased
use of a modern FP method, its evaluation found that
the extent to which it reaches the most disadvantaged
could be improved [20]. This is particularly relevant
given the demonstrated and persistent socio-economic
gap in the use of FP methods in Pakistan [21].
We evaluated the cost, cost-efficiency and cost-ef-
fectiveness of a complex FP programme in Pakistan
which comprised both SF and SM approaches. The
results can inform planning and budgeting decisions
for a potential programme scale-up, as well as, po-
tentially, the adoption and design of similar pro-
grammes elsewhere.
Methods
Setting
The UK Department for International Development
(DFID) funded the Delivering Reproductive Health Re-
sults (DRHR) through Non-State Providers programme
to support non-state service providers over four years
(2012–2016) to expand the delivery and utilisation of
high-quality reproductive health services and commod-
ities in under-served urban and rural areas in southern
Punjab, northern Sindh, Khyber Pakhtunkhwa and Fed-
erally Administered Tribal Areas (FATA). The project
started with two implementing partners using different
approaches to scale up access to and use of modern fam-
ily planning services: Marie Stopes International (MSI),
working through its local branch Marie Stopes Society
(MSS), used a SF model; and Population Services Inter-
national (PSI), working with its local counterpart Green-
star Social Marketing (GSM), used a SM approach.
Description of interventions
In the SF sub-programme, MSI has used the MSS ‘Suraj’
model whereby a network of Suraj franchises (Suraj A
and Suraj B clinics) were trained on client-centred ser-
vices, counselling and side-effect management. Suraj
clinics are essentially partnerships with local private
health services providers located in peri-urban and rural
areas at an average distance of 40–80 km from district
headquarters. They are supported by reproductive health
private providers (RHPPs) called ‘Pehli Kiran’, which are
supplied with contraceptives to provide short-term and
intrauterine devices (IUD) services. Pehli Kiran are ser-
vice providers particularly targeting far-flung rural com-
munities and represent more than 90% of providers in
the franchised network. The project trains them in com-
munity mobilisation and information, education and
communication (IEC) utilising existing materials. Behav-
iour change communication and marketing activities in-
volve distributing vouchers for family planning services
through a network of field worker marketing agents
(FWMs) to help increase the health seeking behaviour of
the poor and under-served for family planning services.
FWMs conduct door-to-door visits to market the Suraj
brand and services, mobilise the community, generate
referrals and distribute vouchers to potential clients
based on a poverty assessment. The vouchers entitle
those who obtain them to have an IUD insertion for free
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at franchised providers. Those who do not qualify for
the voucher pay the full amount (200Pakistani rupees).
In the SM sub-programme, PSI has supplied SM com-
modities, products and advice for RH (mainly FP), along
with demand side interventions, in under-served urban
and rural areas. Similar to SF, the approach ad-
dresses both the demand side and the supply side of
family planning/reproductive health commodity and
service provision. PSI working through their affiliate,
GSM, use a total market approach which includes
commercial for-profit products, social marketed sub-
sidised products and products that are free for the
poorest. To empower women and girls to make
healthy reproductive choices, GSM and its imple-
menting partners reach young women, men and key
influencers like health care providers, husbands and
mothers in law, with evidence-informed messages
promoted through interpersonal communication. In
Year 3, GSM also relaunched and strengthened its
toll-free helpline, which provides family planning
and sexual health and reproductive health informa-
tion, counselling and referrals.
Design
We evaluated the cost, cost-efficiency and cost-effective-
ness of the DRHR programme and its components (SM
and SF). For the cost analysis, both programme costs
and user costs were calculated. Programme costs refer
to the cost of activities undertaken by the implementing
partners to provide services and commodities. User costs
refer to costs that individuals are subject to when acces-
sing products and services offered as part of the
programme. Monetary costs include out-of-pocket
(OOP) payments to cover the sale prices of commod-
ities/services, professional fees, transport to the service
provider and, if applicable, accommodation. Non-monet-
ary costs include the value of productive time lost by the
user and anyone accompanying them to the service pro-
vider, as well as social sanctions stemming from cultural
perceptions of services and others. The analysis included
only monetary costs.
The cost per couple years of protection (CYP) and cost
per new user were estimated as indicators of cost-efficiency.
Three cost-effectiveness indicators were estimated: cost per
maternal death averted; cost per unsafe abortion averted;
and cost per unintended pregnancy averted.
Data sources
To estimate programme costs, quarterly invoices and ex-
penditure reports sent to DFID by MSI and PSI were ob-
tained. We requested additional information from each
implementing partner on: staff costs; volumes and prices
of commodities purchased and disbursed; the internal
charts of accounts; and cost recovery arrangements. User
cost data were collected using a pre-post survey whose
methodology and findings were reported elsewhere [22].
Briefly, 7888 statistically representative households were
surveyed in 400 clusters at baseline (mid-2013) and 6336
households were successfully followed up at endline (late
2015). Costs and outcomes were compared between mar-
ried women of reproductive age (MWRAs) in two DRHR
evaluation groups (a ‘PSI only’ group and a ‘combined MSI
and PSI’ group) and those who were not exposed to either
PSI or MSI activities (control). The sampling strategy was
based on randomly selecting evaluation clusters from one
of the three groups, at the sub-district (tehsil) level. The
evaluation used a combination of propensity score match-
ing (PSM) and differences in differences methods to esti-
mate the changes in costs and outcomes (access, utilisation,
equity and quality of care) that can be attributed to the pro-
grammes. The analysis of user costs was informed by the
panel dataset of women (n = 5514) who participated in both
the baseline and endline surveys.
For cost-efficiency indicators, the cost term in ‘cost
per CYP’ and ‘cost per new user’ was informed by total
programme costs. CYP estimates were sourced from re-
ports of the implementing partners.
Analysis
Both financial and economic costs were calculated [23].
The analysis of financial costs took a top-down approach
in which the programme budget was disaggregated into
cost categories. All programme costs are expressed in
British pounds (GBP, 2015 value). Given that implement-
ing partners invoiced programme expenditures in GBP,
expenditures incurred in 2012–2014 were first converted
to Pakistani rupees (PKR), inflated to their 2015 values
using Pakistan’s annual inflation rate for 2012–2014,
[24] and then converted back into GBP using the aver-
age exchange rate for the last quarter of the evaluation
period (July – September 2015) [25].
Economic costs were estimated as the sum of financial
costs with annuitisation, the value of commodity subsid-
ies and programme cost recovery. Financial costs with
annuitisation were calculated by subtracting the value of
fixed assets from financial costs, then calculating and
adding back capital depreciation for each programme
year. Capital depreciation was calculated using the
straight line method based on the useful life in the asset
register or assuming a useful life of five years (when use-
ful life was not recorded in the asset register), and a sal-
vage value of 10% of the acquisition price [26]. The
value of commodity subsidies was estimated by multiply-
ing the number of commodity units acquired at subsi-
dized price by the difference between the acquisition
price (assumed zero if donated) and corresponding mar-
ket prices. Cost recovery (income that implementation
partners make as a result of programme operations) was
Gheorghe et al. Global Health Research and Policy            (2018) 3:33 Page 3 of 10
incorporated as a cost incurred at the moment when it
was collected (subtracted from financial cost); in the ab-
sence of any indication to suggest otherwise, it was as-
sumed that these funds were not reinvested in the
programme and did not lead to additional outputs.
Two types of ‘cost per new user’ were estimated: one
based on new users reported by the implementers
through their field activities (PSI/GSM recorded new
users from Year 2 onwards); and another calculated
based on self-reported FP method use in the survey data.
Given the distinctions between three types of users
(users of FP methods at baseline, but not at endline;
constant users or non-users at both baseline and end-
line; and users of FP methods at endline only), the group
‘users of FP methods at endline only’ was used to esti-
mate total new users for the purpose of this analysis i.e.
women who reported not using a modern family plan-
ning method at the baseline survey, but did report using
a method at endline, and were not pregnant at either
baseline or endline. We extrapolated ‘new users’ as de-
fined above using survey sampling weights to the popu-
lation from which respondents were sampled, thus
estimating total new users for each evaluation group.
Cost-effectiveness indicators were estimated by divid-
ing total programme costs by the cumulative clinical
events averted as reported by each implementing part-
ner. Additionally, disability-adjusted life years (DALYs)
averted were estimated using the MSI Impact 2 calcula-
tor [27] based on commodity data provided by the
implementing partners. An incremental analysis was also
performed for SM and SF against each other by calculat-
ing an incremental cost-effectiveness ratio through div-
iding the difference in costs by the difference in
outcomes averted between them. The rationale for the
incremental analysis is that cost-effectiveness analysis
can appropriately inform decision-making only if the
intervention of interest is compared against the best
available alternative. As such, a decision-maker faced
with choosing either SM or SF as a model to deliver FP
services, if such a decision is viable, will be interested
not only in how they compare individually against ‘doing
nothing’ but also against each other.
No time adjustment was applied to measures of health
benefit in the cost-efficiency and cost-effectiveness ana-
lyses in the understanding that these benefits occur in
the same period (e.g. year of programme) as that in
which they are reported.
Results
Programme costs
The DRHR programme spent £19,389,941 (GBP 2015
value) between July 2012 and September 2015 on SM
and SF sub-programmes (Table 1). Two thirds of DRHR
funds (65%) were spent on reimbursables and the
remaining 35% on staff salaries. Compared to the financial
costs, economic costs were higher by approximately
£885,000 (8.5% of financial costs) in the SF sub-programme
and lower by approximately £1,665,000 (15% of financial
costs) in the SM sub-programme. Economic costs in the
SM sub-programme are underestimated considering that
the value of subsidized commodities could not be calcu-
lated due to insufficient data.
User costs
The proportion of clients who reportedly incurred
transport costs to reach the nearest family planning
method provider remained constant in all arms of
the impact evaluation (Table 2). Respondents in the
control arm spent on average 65 PKR less (p-value
0.05) on transport at endline than at baseline, while
in the SM and SM + SF arm transport cost differ-
ences were of similar magnitude and were not statis-
tically significant.
In the control arm the proportion of respondents
who had to pay anything to obtain contraceptive
method decreased from 51 to 25% (p 0.06) and the
mean spend on contraceptive methods increased by
510 PKR, though this increase was not statistically
significant (Table 2). In the SM-only arm, more
respondents had to pay to obtain contraceptive
methods, however the average amount spent de-
creased by 133 PKR (p-value 0.03). There were no
significant changes from baseline in the SM + SF
arm. The average spending differences require a cau-
tious interpretation because of the limited number of
responses in each arm (n < 100) as this question was
asked only to survey respondents who were: current
users of FP, had obtained FP in the past 3 months,
and had to pay something for their FP.
Table 1 Economic and financial costs of the DRHR programme
SM SF Total
Financial costs (GBP)
Fees 1,084,009 6,052,910 7,136,919
Reimbursables 8,308,875 5,168,704 13,477,579
Total 9,392,884 11,221,614 20,614,499
Economic costs (GBP)
Equipment cost 132,324 1,279,427 1,411,751
Capital depreciation 114,113 350,409 464,522
Commodity subsidies NA 46,469 46,469
Cost recovery 458,602 2726 461,328
Total 9,833,275 10,341,792 20,175,067
MSI and PSI expenditure data and OPM calculations
NA – data not available. Costs cover the entire duration of the programme up
to when this analysis was conducted (Q1-Q13) and are calculated as: Total
financial cost (2015 value) – equipment cost + capital depreciation +
commodity subsidies + cost recovery
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Cost-efficiency
In total 3,987,517 CYPs were delivered across the two
sub-programmes, leading to a cumulative cost-efficiency
of £4.76 per CYP (GBP 2015 value). The average cost per
CYP delivered was £5.69 in the SF sub-programme and
£4.10 in the SM sub-programme (Table 3). Estimated
economic costs per CYP were lower than financial costs
for the SF programme (£5.21) and higher in the SM
programme (£4.37).
MSI estimated that the SF sub-programme attracted
462,542 new users from inception to June 2015.
When considering the £10,436,488 (2015 value) ex-
penditure during the same period, this leads to an
estimated £22.6 per new user. PSI/GSM reported
162,832 new users for Year 2 and Year 3. Considering the
£6,876,494 (2015 value) sub-programme expenditure in-
curred during the same period, this leads to an estimated
£42.2 per new user.
Approximately 14% of survey respondents in MSI and
PSI areas appear to be new users, more than in PSI only
areas (9.1%) and closely comparable to control areas
(Fig. 1). There is evidence of discontinuation, reflected
in self-reported users at baseline who were not family
planning methods users at endline: 10% in MSI and PSI
areas, less than in control (18%) and comparable to PSI
only areas (11%). By extrapolating survey data based on
survey sampling weights we estimated 216,791 new users
in SM + SF areas, pointing to a cost of £43.6 per new
user for the SF sub-programme.
Cost-effectiveness
We estimated a cost of £20 per DALY averted and £21 per
unintended pregnancy averted for the DRHR programme
(Table 4). For the SF sub-programme we estimated a cost
of £22 per DALY averted and £11,258 per maternal death
averted. For the SM sub-programme, the cost per unin-
tended pregnancy averted is somewhat higher than for SF
(£23 compared to £16), while the cost per abortion
averted is somewhat lower (£104 compared to £148). With
the exception of unsafe abortions, the SF sub-programme
was more costly and also more effective than the SM
sub-programme. When comparing SM to SF in an incre-
mental analysis, SF would avert one unintended preg-
nancy for an additional expense of £3, avert one maternal
death for an additional £3324 and avert one DALY for an
additional £24.
Discussion
Summary of findings
Approximately £20 million were spent through the DRHR
programme between July 2012 and September 2015 on
commodities and services representing nearly four million
CYPs. Based on programme data, the cumulative cost-effi-
ciency of the entire DRHR programme was £4.8 per CYP
(2015 value). Similarly, DRHR activities would avert one
DALY at the cost of £20. Financial access indicators gener-
ally improved in programme areas, but the magnitude of
Table 2 User costs for transport and FP methods
Control SM only SM and SF
Baseline Endline Difference Baseline Endline Difference Baseline Endline Difference
Transport cost to nearest family planning method provider
Of those visiting RH provider, % that spent any
money on transport
26.7 21.6 −0.05 52.5 55.4 0.03 28.3 31.4 0.03
Mean spend on transport to each nearest RH provider
(PKR)
140.4 75.8 −64.7** 96.0 159.6 63.6 127.7 70.6 −57.1
Cost to obtain family planning method at provider
% MWRAs spending any money to obtain
contraceptive method last time
50.8 24.6 −26.2* 53.2 69.5 16.3** 43.8 34.5 − 9.3
Mean spend on obtaining contraceptive method last
time
(PKR)
68.9 579.0 510.1 254.1 121.3 − 132.8** 146.9 152.9 6.0
OPM analysis of MSI/PSI baseline and endline surveys
Asterisks indicate that the difference between the baseline and endline value is statistically significant
*= significant at 10% level
**= significant at 5% level
***= significant at 1% level
Table 3 Cost per CYP in DRHR
Indicator SM SF Total
CYPs achieved 2,151,994 1,835,523 3,987,517
Financial costs (GBP) 8,833,446 10,436,488 19,269,934
Financial costs per CYP 4.10 5.69 4.83
Economic costs (GBP) 9,412,820 9,556,665 18,969,485
Economic costs per CYP 4.37 5.21 4.76
At the time of the analysis MSI reported actual CYPs only for the period July
2012 – June 2015 (Q1-Q12, excluding Q13). For consistency, in this analysis
costs and CYPs incurred during quarters 1–12 were considered for both SM
and SF. Financial and economic costs for both SF and SM are lower than
reported in Table 1, the differences representing costs incurred during Q13
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progress varies across indicators. Improvements in control
areas have been comparable to – if not better than – im-
provements in programme areas [22, 28]. We present key
findings of the impact assessment in Additional file 1: Ap-
pendix 1.
Interpretation of findings
Our findings need to be viewed in reference to the
broader family planning context in Pakistan. While
Demographic and Health Survey (DHS) data indicate re-
ductions in unmet need for family planning over time
(from 31% in 1990–91 to 17% in 2017–18), the use of
modern contraceptive methods and proportion of
women with demand satisfied with modern contracep-
tive methods have remained largely stationary in
Pakistan over the past five years at 25 and 49%, respect-
ively [29]. The cultural determinants of access to family
planning services and products are complex in Pakistan
– while knowledge of at least some contraceptive
methods may be high, there are multiple barriers to
contraceptive use which include but are not limited to:
religion (e.g. religious imperative to have as many chil-
dren as possible), fear of side-effects (e.g. bleeding after
contraceptive injection), social stigma (e.g. disapproval
in the community), family stigma (e.g. pressure from
husband or in-laws), limited female mobility (e.g. women
not allowed to travel alone) and others [19]. The deci-
sion to use contraceptives is hardly an individual one, as
the views of a woman’s husband and in-laws may often
prove decisive.
Assessing whether DRHR offered good value for money
depends on the availability of acceptable benchmarks. In
the absence of universal benchmarks for the cost per CYP
and the cost per new user, we compared our findings with
those of similar programmes. We identified in the Univer-
sity of California at San Francisco (UCSF) Clinical Social
Franchising Compendium 2014 [30] seven SF pro-
grammes (in Democratic Republic of Congo, Guatemala,
Haiti, Madagascar, Malawi, Senegal and Sierra Leone) for
which we could calculate the cost per CYP, which ranged
from £3.5 (Senegal) to £92.5 (Haiti), with five of seven esti-
mates below £10 per CYP (Additional file 1: Appendix 2).
Fig. 1 Estimated users at baseline and endline, by residence (%). Survey data and OPM calculations
Table 4 Cost-effectiveness indicators for DRHR
Indicator SF SM Total Incremental analysis (SF-SM)
Unintended pregnancies 648,629 300,763 949,392 347,866
Maternal deaths 927 613 1540 314
Unsafe abortions 70,673 70,860 141,533 −187
DALY averted 517,423 473,737 991,160 43,686
Financial costs (GBP) 10,436,488 9,392,884 19,829,372 1,043,604
Cost per unintended pregnancy averted 16 23 21 3
Cost per maternal death averted 11,258 12,145 12,876 3324
Cost per unsafe abortion averted 148 104 140 SF is dominated
Cost per DALY averted 22 20 20 24
MSI and PSI data and OPM calculations
Cost and outcomes data on unintended pregnancies averted, maternal deaths averted and unsafe abortions averted are as supplied by MSI (up to June 2015).
Cost per unintended pregnancy averted, maternal death averted and unsafe abortion averted for MSI are informed by programme costs up to June 2015
(£10,438,488). DALYs averted were calculated using the MSI Impact 2 model based on the product mix data supplied by MSI and PSI. All DALYs averted until 2019
(the longest-acting family planning method delivered in DRHR, other than sterilisation, was assumed to provide protection for 5 years) were aggregated
without discounting
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An evaluation of an injectable contraceptive program
combining community-based distribution and SM in
Ethiopia found an average programmatic cost of $17 per
CYP (approximately £13) and a direct cost service cost of
$2 (approximately £1.5) [31]. Two annual reviews of
DFID-funded RH projects reported a cumulative cost of
£14.5 per CYP and £13 per additional user (Zambia [32]);
and £6.4 per CYP (nine countries in sub-Saharan Africa
and five countries in southern Asia [33]). Finally, estimates
for Pakistan suggest the public sector delivers FP services
at an average cost of $17 (approximately £13) per CYP
[34]; and a modelling study looking at social marketing
alone suggested an average incremental cost of $4.3 (ap-
proximately £3.2) per CYP [35]. While the findings of
these studies are difficult to compare directly because of
differences due to setting (e.g. country, urban/rural mix of
providers and beneficiaries), programme design (e.g. scale
and mix of contraceptive interventions) and methodology
(e.g. impact and cost estimation), their results are consist-
ent in suggesting a range of £3 to £15 for the total cost
per CYP. Given that DRHR and its sub-programmes aver-
aged below £6 per CYP, this suggests they are likely to be
cost-efficient. Some caution is needed, however, because
cost per new user estimates are scarce and difficult to esti-
mate robustly, therefore cost-efficiency is largely informed
by cost per CYP estimates.
External benchmarks are available for the cost per
DALY averted. Thresholds informed by countries’ gross
domestic product (GDP) per capita were long used in
global health [36, 37], informed by the work of the Com-
mission for Macroeconomics and Health [38], before the
World Health Organization recommended country-spe-
cific thresholds for decision-making [39]. The Inter-
national Decision Support Initiative (iDSI) updated these
thresholds based on the likely marginal productivity of
health systems and suggested a cost-effectiveness thresh-
old range for Pakistan of $87–669 (approximately £58–
448) per DALY averted [40]. Furthermore, for the seven
programmes in the UCSF Social Franchising Compen-
dium we calculated a cost per DALY averted ranging
from £2.5 (Sierra Leone) to £133.7 (Haiti), with six of
seven values below £50 per DALY averted. The DRHR,
SF and SM cost per DALY averted estimates compare
favourably against these values, suggesting they can be
considered cost-effective.
It is difficult to say whether SF or SM offered better
value in DRHR. First, the indicators send a mixed mes-
sage. In terms of cost-efficiency, the SF sub-programme
had a slightly higher cost per CYP (£5.69 vs £4.04) and a
lower cost per new user (£22 vs £42) than the SM
sub-programme. In terms of cost-effectiveness, SF and
SM achieved comparable performance for the cost per
DALYs averted (£22 for SF and £20 for SM), maternal
death averted (£11,258 vs £12,145) and unintended
pregnancy averted (£16 vs £23); the only exception was
the cost per unsafe abortion averted, which was higher
in the SF programme (£148 vs £104).
Secondly, caution is warranted when comparing SF
and SM directly because they take different approaches
to delivering impact, with implications for the structure
of expenditures and outcomes. For example, start-up
costs are higher for the SF sub-programme, given the
need to attract and train new franchisees, while the SM
programme relies to a larger extent on an existing net-
work of providers. Furthermore, they take different ap-
proaches to delivering CYPs: the SF sub-programme
relied primarily on long-term methods (97% of CYPs),
while in the SM approach the product mix was more
diverse i.e. condoms (49% CYPs), IUDs (30%) and
contraceptive pills (11%). Differences between estimates
of economic and financial costs illustrate the conse-
quences of such differences on estimating value for
money. Economic costs were lower than financial costs
for the SF sub-programme, a consequence of the
capital-intensive nature of the delivery model; and
higher for the SM sub-programme, given programme
revenues. The latter would have been even higher if
sufficient data had been available to incorporate the
value of commodity subsidies.
There is little evidence to suggest that DRHR activ-
ities contributed to narrowing disparities in access to
FP methods in Pakistan. First, geographical and finan-
cial access improved for both urban/rural and poor/
non-poor respondents [22]. Secondly, the rural and
poor also started from an inferior baseline and the
fact that relative improvements are comparable to
those observed among the better off signals that more
could have been done and remains to be done to
achieve convergence. Furthermore, the absolute im-
provements in financial and geographical access indi-
cators were generally small.
Limitations
Most limitations in the analysis stem from insufficient
data at the appropriate level of disaggregation.
Programme costs could not be disaggregated by activ-
ity and locality (rural/urban). We attempted to con-
duct a top-down activity-based costing exercise, but
we could allocate less than 40% of programme ex-
penditure to specific types of activities (for both MSI
and PSI), therefore we did not include this compo-
nent in the analysis. Difficulties of detailed time
sheets proved to be a major obstacle.
Economic costs are likely to be underestimates. First,
commodity subsidy data were incomplete. Secondly, they
did not incorporate household-level costs, e.g. out-
of-pocket payments for products/services and transport
costs. We decided not to incorporate them in the
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analysis given: i) the limited number of respondents who
reportedly had to pay for services; ii) the low resulting
cost share relative to the total programme expenditure;
and iii) the less than conclusive results in regard to cost
reduction. A full incorporation of the economic costs
would likely make the programme and its compo-
nents appear to offer less value for money than cur-
rently estimated.
CYP and commodity data were sourced from the
implementers’ reports and it was beyond the scope of
this analysis to verify the robustness of these data.
We assumed these values as correct and comparable
between MSI and PSI. However, comparability may
have been affected by slight differences in methodolo-
gies and technique, e.g. applying the United States
Agency for International Development (USAID) con-
version factors to commodities or using the MSI Im-
pact 2 calculator.
Finally, caution must be applied towards the ‘new
users’ estimates because they are sensitive to the def-
inition of ‘new users’. It is difficult to ascertain the
extent to which MSI’s and PSI’s new users tracking
mechanisms cover the entire spectrum of new users
and generate results that are fully comparable with
survey-informed estimates. A fundamental difference
between the two types of estimates is that the survey
allows for a counterfactual while the implementers’
user tracking mechanisms do not. Furthermore, the
difficulties in conducting the activity-based costing
prevented us from using marketing and promotion
costs in the cost per new user formula, which would
have led to a better estimation. Assuming the new
user estimates are correct, our current results most
likely overestimate the cost per new user.
Implications for policy
Our findings suggest that using SM and SF approaches
to increase FP coverage can represent good value for
money in Pakistan and similar contexts. A previous
quasi-experimental evaluation examining the impact of
MSI’s SF approach in the country also found a positive
impact on utilization [41]. Furthermore, our findings
suggest that using SM and SF in combination, particu-
larly in rural areas, may be associated with less discon-
tinuation and more uptake of new contraceptive users
compared with SM in isolation. Nevertheless, when
considering the scale-up of such initiatives policy
makers need to be careful not to overestimate their ef-
fectiveness or their reach among the most disadvan-
taged. A recent evaluation of maternal healthcare
franchises in India and Uganda found a limited ability
of social franchises to reach the poorest areas [42]. As
such, a more complex and context-specific set of
incentives (e.g. area- or income-based schedule of sub-
sidies) and complementarity with supply-side initiatives
should be considered to maximize the potential of SM
and SF approaches.
Further research
The reporting and evaluation of future similar pro-
grammes can benefit from focusing on several as-
pects. One is more effort towards detailed and
harmonised accounting reporting standards across
programme partners. Specifically, this would involve
collecting expenditure data as close to the end user
as possible, as well as introducing activity-oriented
budget lines for both staff and capital, allowing im-
plementers and funders alike to react swiftly to
programme developments. Another is including a
qualitative research component to facilitate a better
understanding of which implementation aspects of
the SM and SF approaches drive impact and value
for money. Possible areas of exploration include: for
beneficiaries – the extent to which programme activ-
ities address key context-specific barriers to contra-
ceptive use (e.g. cultural factors) and reasons for
discontinuation; and the interactions of the
programme with other FP and health-related pro-
grammes. For implementers, it would be important
to establish the extent to which the processes for
selecting and overseeing franchisees (outlets and
clinics) contribute to programme objectives.
We could only find limited research on the value of
SM approaches in delivering reproductive health ser-
vices and commodities – by contrast, more research
has been done for SF. It remains difficult to assess
the relative merits of SF and SM. More research is
necessary to document the implementation, cost and
impact of SM programmes globally.
Conclusions
Our findings add to the scarce literature on the value
for money of market-based approaches to deliver FP
results in low- and middle-income settings. Results
suggest that SM and SF generally provided good value
for money in Pakistan as part of the DRHR
programme when compared with other programmes.
When considering the replication or scale-up of such
interventions, in order to maximize impact policy
makers need to consider carefully how the interven-
tions will reach those who are most in need, what
specific schedule of subsidies or other incentives is
most appropriate for each population sub-group or
geographical area, and how demand creation activities
will complement ongoing supply-side initiatives. Sub-
sequent, more comprehensive evaluations are needed
to nuance the understanding of the determinants of
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impact and value for money in approaches to improv-
ing reproductive health outcomes.
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